 | • レポートコード：MRC2-11QY11593 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はアルジマー病・認知症のグローバル市場について調査・分析したレポートです。種類別（コリン作動性/コリンエステラーゼ（ChE）阻害剤、メマンチン、併用薬（メマンチンとドネペジル）、その他）市場規模、用途別（病院薬局、小売、オンライン販売）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別アルジマー病・認知症の競争状況、市場シェア ・世界のアルジマー病・認知症市場：種類別市場規模 2015年-2020年（コリン作動性/コリンエステラーゼ（ChE）阻害剤、メマンチン、併用薬（メマンチンとドネペジル）、その他） ・世界のアルジマー病・認知症市場：種類別市場規模予測 2021年-2026年（コリン作動性/コリンエステラーゼ（ChE）阻害剤、メマンチン、併用薬（メマンチンとドネペジル）、その他） ・世界のアルジマー病・認知症市場：用途別市場規模 2015年-2020年（病院薬局、小売、オンライン販売） ・世界のアルジマー病・認知症市場：用途別市場規模予測 2021年-2026年（病院薬局、小売、オンライン販売） ・北米のアルジマー病・認知症市場分析：米国、カナダ ・ヨーロッパのアルジマー病・認知症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのアルジマー病・認知症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のアルジマー病・認知症市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのアルジマー病・認知症市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merz Pharma、Novartis、Allergan、Pfizer、Daiichi Sankyo Company、Ono Pharmaceutical、Johnson & Johnson、Eisai、H. Lundbeck、F. Hoffmann-La Roche ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market,
Market Analysis and Insights: Global Dementia Associated with Alzimer’s Disease Market
The global Dementia Associated with Alzimer’s Disease market size is projected to reach US$ 4328.3 million by 2026, from US$ 4212.1 million in 2020, at a CAGR of 2.6%% during 2021-2026.
Global Dementia Associated with Alzimer’s Disease Scope and Market Size
Dementia Associated with Alzimer’s Disease market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dementia Associated with Alzimer’s Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Merz Pharma
Novartis
Allergan
Pfizer
Daiichi Sankyo Company
Ono Pharmaceutical
Johnson & Johnson
Eisai
H. Lundbeck
F. Hoffmann-La Roche
Market segment by Type, the product can be split into
Cholinergic/ Cholinesterase (ChE) Inhibitors
Memantine
Combined Drug (Memantine & Donepezil)
Others
Market segment by Application, split into
Hospital Pharmacies
Retail
Online Sales
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Dementia Associated with Alzimer’s Disease Revenue
1.4 Market by Type
1.4.1 Global Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Cholinergic/ Cholinesterase (ChE) Inhibitors
1.4.3 Memantine
1.4.4 Combined Drug (Memantine & Donepezil)
1.4.5 Others
1.5 Market by Application
1.5.1 Global Dementia Associated with Alzimer’s Disease Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail
1.5.4 Online Sales
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Dementia Associated with Alzimer’s Disease Market Perspective (2015-2026)
2.2 Global Dementia Associated with Alzimer’s Disease Growth Trends by Regions
2.2.1 Dementia Associated with Alzimer’s Disease Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Dementia Associated with Alzimer’s Disease Historic Market Share by Regions (2015-2020)
2.2.3 Dementia Associated with Alzimer’s Disease Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Dementia Associated with Alzimer’s Disease Market Growth Strategy
2.3.6 Primary Interviews with Key Dementia Associated with Alzimer’s Disease Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Dementia Associated with Alzimer’s Disease Players by Market Size
3.1.1 Global Top Dementia Associated with Alzimer’s Disease Players by Revenue (2015-2020)
3.1.2 Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Players (2015-2020)
3.1.3 Global Dementia Associated with Alzimer’s Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Dementia Associated with Alzimer’s Disease Market Concentration Ratio
3.2.1 Global Dementia Associated with Alzimer’s Disease Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Dementia Associated with Alzimer’s Disease Revenue in 2019
3.3 Dementia Associated with Alzimer’s Disease Key Players Head office and Area Served
3.4 Key Players Dementia Associated with Alzimer’s Disease Product Solution and Service
3.5 Date of Enter into Dementia Associated with Alzimer’s Disease Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Dementia Associated with Alzimer’s Disease Historic Market Size by Type (2015-2020)
4.2 Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
5.2 Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
6.2 Dementia Associated with Alzimer’s Disease Key Players in North America (2019-2020)
6.3 North America Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
6.4 North America Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
7 Europe
7.1 Europe Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
7.2 Dementia Associated with Alzimer’s Disease Key Players in Europe (2019-2020)
7.3 Europe Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
7.4 Europe Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
8 China
8.1 China Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
8.2 Dementia Associated with Alzimer’s Disease Key Players in China (2019-2020)
8.3 China Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
8.4 China Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
9 Japan
9.1 Japan Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
9.2 Dementia Associated with Alzimer’s Disease Key Players in Japan (2019-2020)
9.3 Japan Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
9.4 Japan Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
10.2 Dementia Associated with Alzimer’s Disease Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
10.4 Southeast Asia Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
11 India
11.1 India Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
11.2 Dementia Associated with Alzimer’s Disease Key Players in India (2019-2020)
11.3 India Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
11.4 India Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Dementia Associated with Alzimer’s Disease Market Size (2015-2020)
12.2 Dementia Associated with Alzimer’s Disease Key Players in Central & South America (2019-2020)
12.3 Central & South America Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020)
12.4 Central & South America Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Merz Pharma
13.1.1 Merz Pharma Company Details
13.1.2 Merz Pharma Business Overview
13.1.3 Merz Pharma Dementia Associated with Alzimer’s Disease Introduction
13.1.4 Merz Pharma Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020))
13.1.5 Merz Pharma Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Dementia Associated with Alzimer’s Disease Introduction
13.2.4 Novartis Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Allergan
13.3.1 Allergan Company Details
13.3.2 Allergan Business Overview
13.3.3 Allergan Dementia Associated with Alzimer’s Disease Introduction
13.3.4 Allergan Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.3.5 Allergan Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Dementia Associated with Alzimer’s Disease Introduction
13.4.4 Pfizer Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Daiichi Sankyo Company
13.5.1 Daiichi Sankyo Company Company Details
13.5.2 Daiichi Sankyo Company Business Overview
13.5.3 Daiichi Sankyo Company Dementia Associated with Alzimer’s Disease Introduction
13.5.4 Daiichi Sankyo Company Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.5.5 Daiichi Sankyo Company Recent Development
13.6 Ono Pharmaceutical
13.6.1 Ono Pharmaceutical Company Details
13.6.2 Ono Pharmaceutical Business Overview
13.6.3 Ono Pharmaceutical Dementia Associated with Alzimer’s Disease Introduction
13.6.4 Ono Pharmaceutical Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.6.5 Ono Pharmaceutical Recent Development
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Details
13.7.2 Johnson & Johnson Business Overview
13.7.3 Johnson & Johnson Dementia Associated with Alzimer’s Disease Introduction
13.7.4 Johnson & Johnson Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.7.5 Johnson & Johnson Recent Development
13.8 Eisai
13.8.1 Eisai Company Details
13.8.2 Eisai Business Overview
13.8.3 Eisai Dementia Associated with Alzimer’s Disease Introduction
13.8.4 Eisai Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.8.5 Eisai Recent Development
13.9 H. Lundbeck
13.9.1 H. Lundbeck Company Details
13.9.2 H. Lundbeck Business Overview
13.9.3 H. Lundbeck Dementia Associated with Alzimer’s Disease Introduction
13.9.4 H. Lundbeck Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.9.5 H. Lundbeck Recent Development
13.10 F. Hoffmann-La Roche
13.10.1 F. Hoffmann-La Roche Company Details
13.10.2 F. Hoffmann-La Roche Business Overview
13.10.3 F. Hoffmann-La Roche Dementia Associated with Alzimer’s Disease Introduction
13.10.4 F. Hoffmann-La Roche Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020)
13.10.5 F. Hoffmann-La Roche Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Dementia Associated with Alzimer’s Disease Key Market Segments
Table 2. Key Players Covered: Ranking by Dementia Associated with Alzimer’s Disease Revenue
Table 3. Ranking of Global Top Dementia Associated with Alzimer’s Disease Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Cholinergic/ Cholinesterase (ChE) Inhibitors
Table 6. Key Players of Memantine
Table 7. Key Players of Combined Drug (Memantine & Donepezil)
Table 8. Key Players of Others
Table 9. Global Dementia Associated with Alzimer’s Disease Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Dementia Associated with Alzimer’s Disease Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Dementia Associated with Alzimer’s Disease Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Dementia Associated with Alzimer’s Disease Market Share by Regions (2015-2020)
Table 13. Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Dementia Associated with Alzimer’s Disease Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Dementia Associated with Alzimer’s Disease Market Growth Strategy
Table 19. Main Points Interviewed from Key Dementia Associated with Alzimer’s Disease Players
Table 20. Global Dementia Associated with Alzimer’s Disease Revenue by Players (2015-2020) (Million US$)
Table 21. Global Dementia Associated with Alzimer’s Disease Market Share by Players (2015-2020)
Table 22. Global Top Dementia Associated with Alzimer’s Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dementia Associated with Alzimer’s Disease as of 2019)
Table 23. Global Dementia Associated with Alzimer’s Disease by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Dementia Associated with Alzimer’s Disease Product Solution and Service
Table 26. Date of Enter into Dementia Associated with Alzimer’s Disease Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 29. Global Dementia Associated with Alzimer’s Disease Market Size Share by Type (2015-2020)
Table 30. Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Type (2021-2026)
Table 31. Global Dementia Associated with Alzimer’s Disease Market Size Share by Application (2015-2020)
Table 32. Global Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 33. Global Dementia Associated with Alzimer’s Disease Market Size Share by Application (2021-2026)
Table 34. North America Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 36. North America Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 37. North America Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 38. North America Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 39. North America Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 40. Europe Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 42. Europe Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 44. Europe Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 46. China Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 47. China Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 48. China Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 49. China Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 50. China Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 51. China Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 52. Japan Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 54. Japan Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 56. Japan Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 60. Southeast Asia Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 62. Southeast Asia Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 64. India Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 65. India Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 66. India Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 67. India Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 68. India Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 69. India Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Dementia Associated with Alzimer’s Disease Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Dementia Associated with Alzimer’s Disease Market Share (2019-2020)
Table 72. Central & South America Dementia Associated with Alzimer’s Disease Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Dementia Associated with Alzimer’s Disease Market Share by Type (2015-2020)
Table 74. Central & South America Dementia Associated with Alzimer’s Disease Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Dementia Associated with Alzimer’s Disease Market Share by Application (2015-2020)
Table 76. Merz Pharma Company Details
Table 77. Merz Pharma Business Overview
Table 78. Merz Pharma Product
Table 79. Merz Pharma Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 80. Merz Pharma Recent Development
Table 81. Novartis Company Details
Table 82. Novartis Business Overview
Table 83. Novartis Product
Table 84. Novartis Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 85. Novartis Recent Development
Table 86. Allergan Company Details
Table 87. Allergan Business Overview
Table 88. Allergan Product
Table 89. Allergan Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 90. Allergan Recent Development
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Product
Table 94. Pfizer Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 95. Pfizer Recent Development
Table 96. Daiichi Sankyo Company Company Details
Table 97. Daiichi Sankyo Company Business Overview
Table 98. Daiichi Sankyo Company Product
Table 99. Daiichi Sankyo Company Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 100. Daiichi Sankyo Company Recent Development
Table 101. Ono Pharmaceutical Company Details
Table 102. Ono Pharmaceutical Business Overview
Table 103. Ono Pharmaceutical Product
Table 104. Ono Pharmaceutical Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 105. Ono Pharmaceutical Recent Development
Table 106. Johnson & Johnson Company Details
Table 107. Johnson & Johnson Business Overview
Table 108. Johnson & Johnson Product
Table 109. Johnson & Johnson Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 110. Johnson & Johnson Recent Development
Table 111. Eisai Business Overview
Table 112. Eisai Product
Table 113. Eisai Company Details
Table 114. Eisai Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 115. Eisai Recent Development
Table 116. H. Lundbeck Company Details
Table 117. H. Lundbeck Business Overview
Table 118. H. Lundbeck Product
Table 119. H. Lundbeck Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 120. H. Lundbeck Recent Development
Table 121. F. Hoffmann-La Roche Company Details
Table 122. F. Hoffmann-La Roche Business Overview
Table 123. F. Hoffmann-La Roche Product
Table 124. F. Hoffmann-La Roche Revenue in Dementia Associated with Alzimer’s Disease Business (2015-2020) (Million US$)
Table 125. F. Hoffmann-La Roche Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dementia Associated with Alzimer’s Disease Market Share by Type: 2020 VS 2026
Figure 2. Cholinergic/ Cholinesterase (ChE) Inhibitors Features
Figure 3. Memantine Features
Figure 4. Combined Drug (Memantine & Donepezil) Features
Figure 5. Others Features
Figure 6. Global Dementia Associated with Alzimer’s Disease Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Case Studies
Figure 9. Online Sales Case Studies
Figure 10. Dementia Associated with Alzimer’s Disease Report Years Considered
Figure 11. Global Dementia Associated with Alzimer’s Disease Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Dementia Associated with Alzimer’s Disease Market Share by Regions: 2020 VS 2026
Figure 13. Global Dementia Associated with Alzimer’s Disease Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Dementia Associated with Alzimer’s Disease Market Share by Players in 2019
Figure 16. Global Top Dementia Associated with Alzimer’s Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dementia Associated with Alzimer’s Disease as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Dementia Associated with Alzimer’s Disease Revenue in 2019
Figure 18. North America Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
認知症・運動障害治療の世界市場（～2026年） Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality change…- 多発梗塞性認知症の世界市場（～2026年） Multi-cerebral infarction dementia is a series of small strokes that cause disruption of blood flow to the brain. It is the highest incidence among people over 65 years of age. The increase in the global elderly population has also contributed to the development of the global market for multi-infarc…
- アルツハイマー病の世界市場（～2026年） Market Analysis and Insights: Global Alzheimer's Disease Market The global Alzheimer's Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Alzheimer's Disease Scope and Market Size Alzheimer's Disease market is seg…
- アルツハイマー病治療薬の世界市場（～2026年） Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are me…
- クローン病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Crohn’s Disease Drug Market The global Crohn’s Disease Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Crohn’s Disease Drug Scope and Market Size Crohn’s Disease Drug market is…